CDC25 Phosphatases in Cancer Therapeutics

CDC25 phosphatases are dual-specificity enzymes that orchestrate key transitions in the eukaryotic cell cycle by activating cyclin-dependent kinases through dephosphorylation of inhibitory residues. Three isoforms—CDC25A, CDC25B and CDC25C—differ in their temporal and spatial regulation but converge on the control of DNA synthesis entry and mitotic onset. In many cancers, overexpression or dysregulation of CDC25 phosphatases disrupts checkpoint fidelity, promotes unchecked proliferation and fosters genomic instability. These attributes have established CDC25s as attractive targets for therapeutic intervention. Efforts to inhibit CDC25 activity span structure-based drug design, high-throughput screening of small-molecule libraries and exploitation of redox-sensitive active-site cysteines. Successful inhibitors induce cell cycle arrest at G1/S or G2/M, trigger apoptosis in tumour cells and, in preclinical models, achieve tumour regression without overt toxicity. Emerging strategies integrate CDC25 inhibition with precision oncology, pairing molecular profiling with tailored pharmacological regimens to enhance efficacy and limit off-target effects. Ongoing research also examines regulatory networks that modulate CDC25 stability and activity, including feedback loops with kinases and ubiquitin ligases, thereby expanding the scope for combination therapies that reinforce cell cycle checkpoints in resistant malignancies.

Research from Nature Portfolio

Recent studies have harnessed pharmacophore modelling and virtual screening to define minimal interaction motifs common to known CDC25 inhibitors. By leveraging available crystal structures of CDC25A and CDC25B, investigators identified naphthoquinone-based compounds exhibiting mixed-type inhibition via reversible oxidation of catalytic cysteines. These inhibitors effectively arrested cancer cells at the G1/S or G2/M boundary, impaired CDK1 activity and induced mitotic catastrophe followed by cell death. In three-dimensional organoid models of intestinal epithelium harbouring APC and KRAS mutations, treatment prompted differentiation and reduction of stem-like traits. Furthermore, in vivo assays in zebrafish xenografts demonstrated significant tumour regression and diminished metastatic potential, underscoring the translational promise of structure-guided CDC25 inhibitors.

CDC25 Phosphatases in Cancer Therapeutics publication trend

The graph below shows the total number of articles in cdc25 phosphatases in cancer therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

CDC25 phosphatase: An enzyme that removes inhibitory phosphate groups from cyclin-dependent kinases, thereby activating them and driving cell cycle progression.

Cyclin-dependent kinase (CDK): A protein kinase regulated by binding to cyclins and phosphorylation status, essential for orderly cell cycle transitions.

Cell cycle checkpoint: Surveillance mechanisms that assess DNA integrity or completion of critical events (such as replication) before allowing progression to the next phase.

G2/M transition: The cell cycle phase boundary at which cells commit to mitosis, regulated by the activation of CDK1 and its cyclin partners.

References

1. Potential of CDC25 phosphatases in cancer research and treatment: key to precision medicine. Frontiers in Pharmacology (2024).
2. A Comprehensive Overview of the Developments of Cdc25 Phosphatase Inhibitors. Molecules (2022).
3. Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression. Scientific Reports (2019).
4. Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer. Frontiers in Oncology (2019).
5. In Silico Identification of Small Molecules as New Cdc25 Inhibitors through the Correlation between Chemosensitivity and Protein Expression Pattern. International Journal of Molecular Sciences (2021).